NCT06325683 2026-04-21
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
8 trialsNCT06894225 2026-04-20
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
National Neuroscience Institute
Phase 2 Suspended
NCT03952598 2026-04-14
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT05183204 2025-12-18
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Weill Medical College of Cornell University
Phase 2 Suspended
NCT06855628 2025-10-28
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Stanford University
Phase 2 Suspended
NCT02742883 2025-09-16
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Burzynski Research Institute
Phase 2 Suspended
NCT05123534 2024-09-19
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG
SonALAsense, Inc.
Phase 2 Suspended
NCT00003067 2009-02-09
Biological Therapy in Treating Patients With Primary or Advanced Glioma
National Cancer Institute (NCI)
Phase 2 Suspended